“This was a small study, but with a clear enough result that all babies with this form of leukemia now receive immunotherapy as part of standard treatment,” said pediatric oncologist and clinical pharmacologist Inge van der Sluis, who led the study. “In a larger study with more children, we want to confirm the effect of blinatumomab. We also want to see whether babies benefit from two courses of blinatumomab and a reduction in chemotherapy, in order to further improve the quality of life.”
Research: Prognosis of babies with aggressive leukemia greatly improved
